Physician profile
June Kwark
NPI 1154428415
$4,937.98
in general payments reported to CMS, 2019-2025
30 companies · $39.45 in 2025
The $39.45 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $1,856 · 2021: $1,660 · 2022: $436 · 2023: $496 · 2024: $42.52 · 2025: $39.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,694.00 | 2020-2023 | Da Vinci Surgical System |
| Abbvie INC. | $553.28 | 2020-2023 | |
| Mayne Pharma Commercial LLC | $259.89 | 2021-2023 | |
| Daiichi Sankyo INC. | $240.97 | 2019-2024 | Injectafer |
| Therapeuticsmd, INC. | $237.76 | 2019-2022 | |
| Coopersurgical, INC. | $84.09 | 2021-2023 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $77.90 | 2019-2023 | |
| Hologic Sales and Service, LLC | $72.68 | 2023-2025 | Aptima |
| Organon LLC | $71.75 | 2022-2023 | Nexplanon |
| Avion Pharmaceuticals | $69.01 | 2019-2021 | |
| Exeltis, USA INC. | $60.34 | 2021-2023 | Slynd |
| Lupin INC. | $56.13 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $51.50 | 2019-2021 | |
| Allergan, INC. | $38.43 | 2019 | |
| Merck Sharp & Dohme LLC | $34.59 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $33.99 | 2021 | |
| Millicent US INC | $33.37 | 2020 | |
| Mylan Pharmaceuticals INC. | $29.47 | 2021-2022 | |
| Evofem Biosciences, INC. | $29.40 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $24.46 | 2019 | |
| Astellas Pharma US INC | $24.14 | 2024 | Veozah |
| Duchesnay USA Incorporated | $22.75 | 2019 | |
| Aspira Women'S Health INC | $21.05 | 2019 | |
| Shield Therapeutics INC | $19.94 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.79 | 2020 | |
| Becton, Dickinson and Company | $17.72 | 2023 | Bd Onclarity |
| Pfizer INC. | $16.82 | 2022 | |
| Optumhealth Care Solutions, LLC | $15.70 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Covidien LP | $14.96 | 2019 | |
| Myovant Sciences INC. | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw June Kwark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.